Espaa says goodbye to the vaccine AstraZeneca, controversial especially due to the diversion of doses committed to the market british, although it was used as a pretext for its progressive withdrawal from the European Union some problems thrombotic little statistically relevant. In fact, messages were received for some time, both officers, about the paralyzing of the vaccine to study them and the guarantees that were given to their absolute safety.
These problems have caused a delay in the complete immunization of the group of people from 60 to 69 years old, the one to whom the vaccine was determined to be targeted. It remains, still, a million people to receive their second dose, but they will not be left without it nor will they have to be immunized with another compound, since although AstraZeneca comes from general remittances, the corresponding doses will be received for people who still need it.
The doses already bought by Spain will be sent to other countries via system Covax, which provides vaccines to less developed countries. In total, in Spain some 10 million doses of AstraZeneca. Developed by this pharmaceutical company and the University of Oxford, it was the first vaccine to start its development, and it has been the majority in the immunization of the population of the UK.
– .
